REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/19/2026
Back to search
Official data from USPTO
SIEN-NET
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
01/20/2026
Trademark type
Word
Nice classes
5
Filing date
11/08/2019
Registration date
01/19/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/19/2021
Last transaction
01/20/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
83
Owner location
AU
Examiner
LAM,HAI-LY HUYNH
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Sienna Cancer Diagnostics Ltd
Representatives
Charles G. Zug Nelson Mullins Riley & Scarborough LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for the treatment and/or diagnosis of cancer and infectious diseases; biotechnologically-formed enzyme preparations for medical purposes; medicinal preparations for the treatment of cancer and infectious diseases; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicinediagnostic kits consisting primarily of monoclonal antibodies used in the capture of specific biological markers for use in disease testing; proteins for binding antibodies for medical use; proteins for detecting antibodies for medical use; reagents for medical usefor use in the development of monoclonal antibodies; diagnostic biomarker reagents for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancerviralbacterial infection; vaccines for human use; diagnostic preparations and reagents for medical purposes; vaccine adjuvants; diagnostic preparationsreagentssubstances for medical purposes; diagnostic products and testing materials for medical purposesdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in capturing and purifying specific biological markers for use in disease testing; reagents for use in diagnostic tests for medical purposes; medical diagnostic reagents for capturing and purifying specific biological markers that can be utilised in therapeutics or diagnostics; cells for growing recombinant human protein for medical purposes; recombinant DNA technology proteins for medical use; biological reagents for use in molecular biologyreagents for medical use for capturing and purifying specific biological markers that contain nucleic acid; antibodies that are specifically able to bind and capture specific biological markers for medical purposes; antibody fragments that are specifically able to bind and capture specific biological markers for medical purposes; antibody conjugates that are specifically able to bind and capture specific biological markers for medical purposes; pharmaceutical preparations for the treatmentreconstruction and repair of antibodies; immunological antibodies for medical use; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use
Publications
History of USPTO decisions and trademark events.
26 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/16/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/23/2021
FIMP
FINAL DISPOSITION PROCESSED
04/23/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/19/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/29/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
01/19/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/03/2020
PUBO
PUBLISHED FOR OPPOSITION
11/03/2020
GPNX
NOTIFICATION PROCESSED BY IB
11/02/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/14/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/14/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/14/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/24/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/09/2020
RFNT
REFUSAL PROCESSED BY IB
03/27/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/09/2020
RFRR
REFUSAL PROCESSED BY MPU
03/09/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/19/2020
CNRT
NON-FINAL ACTION WRITTEN
02/18/2020
DOCK
ASSIGNED TO EXAMINER
02/12/2020
MAFR
APPLICATION FILING RECEIPT MAILED
12/27/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/23/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/19/2019
Continuous trademark protection
Get notified about every new filing that threatens SIEN-NET or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.